Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
Extended Observational Study on the Long-term Impact of Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Patients With Bronchiectasis: The ERASE II Study
Shanghai Pulmonary Hospital, Shanghai, China
364 participants
Oct 16, 2024
OBSERVATIONAL
Conditions
Summary
The ERASE II study is a prospective follow-up study designed to assess the long-term impact of successful eradication of Pseudomonas aeruginosa (PA) in patients with bronchiectasis. Building on the findings of the initial ERASE study, which evaluated the efficacy and safety of Tobramycin Inhalation Solution, ERASE II aims to determine whether successful PA eradication influences patient prognosis over an extended period. The study will involve a total observation period of 36 months, consisting of the initial 9 months of the ERASE study followed by an additional 27 months of comprehensive follow-up. Key outcomes to be assessed include patients' quality of life, lung function, frequency of pulmonary exacerbations, frequency of hospitalization, and overall treatment costs. Additionally, the study will examine the timing and incidence of any potential reinfections with Pseudomonas aeruginosa.
Eligibility
Inclusion Criteria2
- all patients who participate the ERSE study
- write the informed consent form.
Exclusion Criteria2
- patients who were lost of follow up in the ERASE study
- ineligible for inclusion at the discretion of the researcher for other reasons.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Observational study, no additional intervention
Locations(58)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06760273